{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T06:55:32Z","timestamp":1791356132769,"version":"4.3.1"},"reference-count":101,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,3,1]],"date-time":"2016-03-01T00:00:00Z","timestamp":1456790400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2016,3]]},"DOI":"10.1016\/j.jconrel.2016.01.056","type":"journal-article","created":{"date-parts":[[2016,1,30]],"date-time":"2016-01-30T03:04:32Z","timestamp":1454123072000},"page":"269-282","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":66,"special_numbering":"C","title":["Reformulating cyclosporine A (CsA): More than just a life cycle management strategy"],"prefix":"10.1016","volume":"225","author":[{"given":"Melissa","family":"Guada","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Beloqui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.N.V. Ravi","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00e9ronique","family":"Pr\u00e9at","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria del Carmen","family":"Dios-Vi\u00e9itez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria J.","family":"Blanco-Prieto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2016.01.056_bb0005","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.biotechadv.2011.03.004","article-title":"Cyclosporin A \u2014 a review on fermentative production, downstream processing and pharmacological applications","volume":"29","author":"Survase","year":"2011","journal-title":"Biotechnol. Adv."},{"key":"10.1016\/j.jconrel.2016.01.056_bb0010","doi-asserted-by":"crossref","first-page":"338","DOI":"10.3109\/10428190903470851","article-title":"Long-term safety and efficacy of cyclosporin A therapy for T-cell large granular lymphocyte leukemia","volume":"51","author":"Pawarode","year":"2010","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.jconrel.2016.01.056_bb0015","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1227\/NEU.0b013e31820c6cdc","article-title":"A review of laboratory and clinical data supporting the safety and efficacy of cyclosporin A in traumatic brain injury","volume":"68","author":"Lulic","year":"2011","journal-title":"Neurosurgery"},{"key":"10.1016\/j.jconrel.2016.01.056_bb0020","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.npep.2011.04.002","article-title":"Cyclosporine-A as a neuroprotective agent against stroke: its translation from laboratory research to clinical application","volume":"45","author":"Osman","year":"2011","journal-title":"Neuropeptides"},{"key":"10.1016\/j.jconrel.2016.01.056_bb0025","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1208\/s12248-011-9259-8","article-title":"The immunosuppressive activity of polymeric micellar formulation of cyclosporine A: in vitro and in vivo studies","volume":"13","author":"Hamdy","year":"2011","journal-title":"AAPS J."},{"key":"10.1016\/j.jconrel.2016.01.056_bb0030","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1166\/jbn.2012.1400","article-title":"Solid self-nanoemulsifying cyclosporine A pellets prepared by fluid-bed coating: stability and bioavailability study","volume":"8","author":"Lei","year":"2012","journal-title":"J. Biomed. Nanotechnol."},{"key":"10.1016\/j.jconrel.2016.01.056_bb0035","first-page":"601","article-title":"Preparation and in vitro and in vivo characterization of cyclosporin A-loaded, PEGylated chitosan-modified, lipid-based nanoparticles","volume":"8","author":"Zhang","year":"2013","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.jconrel.2016.01.056_bb0040","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1016\/j.ijpharm.2014.11.030","article-title":"Sylysia 350\/Eudragit S100 solid nanomatrix as a promising system for oral delivery of cyclosporine A","volume":"478","author":"Dai","year":"2015","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2016.01.056_bb0045","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1080\/03639040601155665","article-title":"Cyclosporine A: a review of current oral and intravenous delivery systems","volume":"33","author":"Beauchesne","year":"2007","journal-title":"Drug Dev. Ind. Pharm."},{"key":"10.1016\/j.jconrel.2016.01.056_bb0050","doi-asserted-by":"crossref","first-page":"3757","DOI":"10.1021\/jm00076a002","article-title":"Solvent-dependent conformation and hydrogen-bonding capacity of cyclosporin A: evidence from partition coefficients and molecular dynamics simulations","volume":"36","author":"El Tayar","year":"1993","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.jconrel.2016.01.056_bb0055","series-title":"Anonymous Metabolic Control in Diabetes Mellitus Beta Adrenoceptor Blocking Drugs NMR Analysis of Cancer Cells Immunoassay in the Clinical Laboratory Cyclosporine","first-page":"157","article-title":"Cyclosporine: chemistry, structure\u2013activity relationships and mode of action","author":"Wenger","year":"1986"},{"key":"10.1016\/j.jconrel.2016.01.056_bb0060","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S0162-3109(00)00192-2","article-title":"Mechanisms of action of cyclosporine","volume":"47","author":"Matsuda","year":"2000","journal-title":"Immunopharmacology"},{"key":"10.1016\/j.jconrel.2016.01.056_bb0065","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/jvim.12265","article-title":"Oral cyclosporine treatment in dogs: a review of the literature","volume":"28","author":"Archer","year":"2014","journal-title":"J. Vet. Intern. Med."},{"key":"10.1016\/j.jconrel.2016.01.056_bb0070","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1111\/j.1476-5381.2011.01700.x","article-title":"Cyclosporin A and cardioprotection: from investigative tool to therapeutic agent","volume":"165","author":"Hausenloy","year":"2012","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.jconrel.2016.01.056_bb0075","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1097\/00007691-199111000-00001","article-title":"Factors influencing the pharmacokinetics of cyclosporine in man","volume":"13","author":"Lindholm","year":"1991","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.jconrel.2016.01.056_bb0080","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/0009-9120(91)90084-R","article-title":"Pharmacology and pharmacokinetics of cyclosporine","volume":"24","author":"Freeman","year":"1991","journal-title":"Clin. Biochem."},{"key":"10.1016\/j.jconrel.2016.01.056_bb0085","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/0163-7258(93)90059-M","article-title":"Cyclosporin metabolism in transplant patients","volume":"57","author":"Christians","year":"1993","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.jconrel.2016.01.056_bb0090","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/S0140-6736(83)90978-9","article-title":"Cyclosporin in cadaveric renal transplantation: one-year follow-up of a multicentre trial","volume":"322","author":"European Multicentre Trial Group","year":"1983","journal-title":"Lancet"},{"key":"10.1016\/j.jconrel.2016.01.056_bb0095","doi-asserted-by":"crossref","first-page":"5785","DOI":"10.4049\/jimmunol.1390055","article-title":"Calcineurin inhibitors: 40years later, can't live without","volume":"191","author":"Azzi","year":"2013","journal-title":"J. Immunol."},{"key":"10.1016\/j.jconrel.2016.01.056_bb0100","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1097\/01.mib.0000235096.78736.8e","article-title":"Treatment of ulcerative colitis refractory to steroid therapy by oral microemulsion cyclosporine (neoral)","volume":"12","author":"Weber","year":"2006","journal-title":"Inflamm. Bowel Dis."},{"key":"10.1016\/j.jconrel.2016.01.056_bb0105","first-page":"677","article-title":"Cyclosporine versus infliximab for the treatment of severe ulcerative colitis","volume":"7","author":"Kornbluth","year":"2011","journal-title":"Gastroenterol. Hepatol."},{"key":"10.1016\/j.jconrel.2016.01.056_bb0110","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.leukres.2013.01.017","article-title":"Treatment of T-cell large granular lymphocyte leukemia with cyclosporine A: experience in a Chinese single institution","volume":"37","author":"Zhao","year":"2013","journal-title":"Leuk. Res."},{"key":"10.1016\/j.jconrel.2016.01.056_bb0115","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1016\/j.drudis.2006.07.015","article-title":"Disease, destination, dose and delivery aspects of ciclosporin: the state of the art","volume":"11","author":"Italia","year":"2006","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.jconrel.2016.01.056_bb0120","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1515\/CCLM.2004.242","article-title":"Therapeutic monitoring of immunosuppressant drugs. Where are we?","volume":"42","author":"Wallemacq","year":"2004","journal-title":"Clin. Chem. Lab. Med."},{"key":"10.1016\/j.jconrel.2016.01.056_bb0125","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/0896-8411(92)90033-M","article-title":"The optimal use of cyclosporin A in autoimmune diseases","volume":"5","author":"Feutren","year":"1992","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.jconrel.2016.01.056_bb0130","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1159\/000351648","article-title":"Calcineurin inhibitor nephrotoxicity: a review and perspective of the evidence","volume":"37","author":"Issa","year":"2013","journal-title":"Am. J. Nephrol."},{"key":"10.1016\/j.jconrel.2016.01.056_bb0135","series-title":"Electrolyte and Acid\u2013Base disturbances induced by clacineurin inhibitors","first-page":"126","volume":"5","author":"Lee","year":"2007"},{"key":"10.1016\/j.jconrel.2016.01.056_bb0140","doi-asserted-by":"crossref","first-page":"481","DOI":"10.2215\/CJN.04800908","article-title":"Calcineurin inhibitor nephrotoxicity","volume":"4","author":"Naesens","year":"2009","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"10.1016\/j.jconrel.2016.01.056_bb0145","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1146\/annurev.me.37.020186.001243","article-title":"Action and toxicity of cyclosporine","volume":"37","author":"Bennet","year":"1986","journal-title":"Annu. Rev. Med."},{"key":"10.1016\/j.jconrel.2016.01.056_bb0150","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/BF01046702","article-title":"Intraindividual variability in the relative systemic availability of cyclosporin after oral dosing","volume":"34","author":"Lindholm","year":"1988","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.jconrel.2016.01.056_bb0155","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1023\/A:1023481418576","article-title":"Human jejunal permeability of cyclosporin A: influence of surfactants on P-glycoprotein efflux in caco-2 cells","volume":"20","author":"Chiu","year":"2003","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2016.01.056_bb0160","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/S0161-5890(03)00077-4","article-title":"Impact of physical properties of formulations on bioavailability of active substance: current and novel drugs with cyclosporine","volume":"39","author":"Andrysek","year":"2003","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.jconrel.2016.01.056_bb0165","doi-asserted-by":"crossref","first-page":"374","DOI":"10.2215\/CJN.03791106","article-title":"Therapeutic monitoring of calcineurin inhibitors for the nephrologist","volume":"2","author":"Schiff","year":"2007","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"10.1016\/j.jconrel.2016.01.056_bb0170","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1097\/01.tp.0000188688.15639.03","article-title":"Does bioequivalence between modified cyclosporine formulations translate into equal outcomes?","volume":"80","author":"Taber","year":"2005","journal-title":"Transplantation"},{"key":"10.1016\/j.jconrel.2016.01.056_bb0175","unstructured":"B. Steve Campbell, E. Elm\u00e9r, M. Bronnegard, TBI Pharmaceuticals\u2014The long odyssey of cyclosporine is almost over, http:\/\/www.internationalbrain.org\/tbi-pharmaceuticals-the-long-odyssey-of-cyclosporine\/ (last access: 10\/22\/2015)."},{"key":"10.1016\/j.jconrel.2016.01.056_bb0180","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s40261-012-0029-x","article-title":"Bioequivalence and tolerability assessment of a novel intravenous ciclosporin lipid emulsion compared to branded ciclosporin in cremophor\u00ae EL","volume":"33","author":"Ehinger","year":"2013","journal-title":"Clin. Drug Invest."},{"key":"10.1016\/j.jconrel.2016.01.056_bb0185","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1023\/A:1016212804288","article-title":"A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability","volume":"12","author":"Amidon","year":"1995","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2016.01.056_bb0190","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1093\/ndt\/16.3.580","article-title":"Effect of 6weeks of vitamin E administration on renal haemodynamic alterations following a single dose of neoral in healthy volunteers","volume":"16","author":"Barany","year":"2001","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.jconrel.2016.01.056_bb0195","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S0939-6411(03)00138-3","article-title":"Cyclosporine A delivery to the eye: A pharmaceutical challenge","volume":"56","author":"Lallemand","year":"2003","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.jconrel.2016.01.056_bb0200","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.ijpharm.2010.10.008","article-title":"Thiolated nanostructured lipid carriers as a potential ocular drug delivery system for cyclosporine A: improving in vivo ocular distribution","volume":"402","author":"Shen","year":"2010","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2016.01.056_bb0205","doi-asserted-by":"crossref","first-page":"37","DOI":"10.3109\/02652040902846883","article-title":"Cyclosporine-A incorporated cationic solid lipid nanoparticles for ocular delivery","volume":"27","author":"Basaran","year":"2010","journal-title":"J. Microencapsul."},{"key":"10.1016\/j.jconrel.2016.01.056_bb0210","doi-asserted-by":"crossref","first-page":"735","DOI":"10.3109\/02652048.2010.517854","article-title":"Chitosan-associated SLN: in vitro and ex vivo characterization of cyclosporine A loaded ophthalmic systems","volume":"27","author":"Sandri","year":"2010","journal-title":"J. Microencapsul."},{"key":"10.1016\/j.jconrel.2016.01.056_bb0215","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S1773-2247(12)50016-X","article-title":"Solid lipid nanoparticles prepared by coacervation method as vehicles for ocular cyclosporine","volume":"22","author":"Battaglia","year":"2012","journal-title":"J. Drug Delivery Sci. Technol."},{"key":"10.1016\/j.jconrel.2016.01.056_bb0220","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.ijpharm.2012.11.009","article-title":"Technology of stable, prolonged-release eye-drops containing cyclosporine A, distributed between lipid matrix and surface of the solid lipid microspheres (SLM)","volume":"441","author":"Wolska","year":"2013","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2016.01.056_bb0225","first-page":"6541","article-title":"Lipid nanoparticles for cyclosporine A administration: development, characterization and in vitro evaluation of their immunosuppression activity","volume":"10","author":"Guada","year":"2015","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.jconrel.2016.01.056_bb0230","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.ijpharm.2016.01.037","article-title":"Lipid nanoparticles enhance the absorption of Cyclosporine A through the gastrointestinal barrier: in vitro and in vivo studies","volume":"500","author":"Guada","year":"2016","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2016.01.056_bb0235","doi-asserted-by":"crossref","first-page":"49633","DOI":"10.1039\/C5RA04762E","article-title":"Cyclosporine A loaded self-nanoemulsifying drug delivery system (SNEDDS): implication of functional Excipient Based Co-encapsulation strategy on oral bioavailability and nephrotoxicity","author":"Jain","year":"2015","journal-title":"RSC Adv."},{"key":"10.1016\/j.jconrel.2016.01.056_bb0240","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.ijpharm.2013.05.014","article-title":"Controlled release of cyclosporine A self-nanoemulsifying systems from osmotic pump tablets: near zero-order release and pharmacokinetics in dogs","volume":"452","author":"Zhang","year":"2013","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2016.01.056_bb0245","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.jconrel.2011.12.016","article-title":"Cyclosporin pro-dispersion liposphere formulation","volume":"160","author":"Avramoff","year":"2012","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2016.01.056_bb0250","doi-asserted-by":"crossref","first-page":"126","DOI":"10.5414\/CPP45126","article-title":"Comparative in vivo bioequivalence and in vitro dissolution of two cyclosporin A soft gelatin capsule formulations","volume":"45","author":"Avramoff","year":"2007","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"key":"10.1016\/j.jconrel.2016.01.056_bb0255","first-page":"965","article-title":"Enhanced oral bioavailability of cyclosporine A by liposomes containing a bile salt","volume":"6","author":"Guan","year":"2011","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.jconrel.2016.01.056_bb0260","doi-asserted-by":"crossref","first-page":"5693","DOI":"10.2147\/IJN.S36883","article-title":"A new approach to the treatment of recurrent aphthous stomatitis with bioadhesive gels containing cyclosporine A solid lipid nanoparticles: in vivo\/in vitro examinations","volume":"7","author":"Karavana","year":"2012","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.jconrel.2016.01.056_bb0265","first-page":"17","article-title":"Cyclosporine A-nanoparticles enhance the therapeutic benefit of adipose tissue-derived stem cell transplantation in a swine myocardial infarction model","volume":"9","author":"Yin","year":"2014","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.jconrel.2016.01.056_bb0270","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.drudis.2012.10.005","article-title":"Recent advances in topical ophthalmic drug delivery with lipid-based nanocarriers","volume":"18","author":"Gan","year":"2013","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.jconrel.2016.01.056_bb0275","doi-asserted-by":"crossref","first-page":"537","DOI":"10.3109\/02713681003760168","article-title":"Feasibility of lipid nanoparticles for ocular delivery of anti-inflammatory drugs","volume":"35","author":"Souto","year":"2010","journal-title":"Curr. Eye Res."},{"key":"10.1016\/j.jconrel.2016.01.056_bb0280","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0939-6411(00)00087-4","article-title":"Solid lipid nanoparticles (SLN) for controlled drug delivery \u2013 a review of the state of the art","volume":"50","author":"M\u00fcller","year":"2000","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.jconrel.2016.01.056_bb0285","doi-asserted-by":"crossref","first-page":"4046","DOI":"10.1021\/bm401141u","article-title":"Development of PLGA-mannosamine nanoparticles as oral protein carriers","volume":"14","author":"Alonso-Sande","year":"2013","journal-title":"Biomacromolecules"},{"key":"10.1016\/j.jconrel.2016.01.056_bb0290","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S0378-5173(01)00760-8","article-title":"Chitosan nanoparticles: a new vehicle for the improvement of the delivery of drugs to the ocular surface. Application to cyclosporin A","volume":"224","author":"De Campos","year":"2001","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2016.01.056_bb0295","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.nano.2015.09.004","article-title":"Nanostructured lipid carriers: promising drug delivery systems for future clinics","volume":"12","author":"Beloqui","year":"2016","journal-title":"Nanomedicine"},{"key":"10.1016\/j.jconrel.2016.01.056_bb0300","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/j.jconrel.2013.09.001","article-title":"An oral malaria therapy: curcumin-loaded lipid-based drug delivery systems combined with \u03b2-arteether","volume":"172","author":"Memvanga","year":"2013","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2016.01.056_bb0305","doi-asserted-by":"crossref","first-page":"286","DOI":"10.3389\/fphar.2015.00286","article-title":"Advances and challenges of liposome assisted drug delivery","volume":"6","author":"Sercombe","year":"2015","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.jconrel.2016.01.056_bb0310","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.4155\/tde.15.69","article-title":"Oral delivery of liposomes","volume":"6","author":"Wu","year":"2015","journal-title":"Ther. Deliv."},{"key":"10.1016\/j.jconrel.2016.01.056_bb0315","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.ijpharm.2012.10.025","article-title":"Integrity and stability of oral liposomes containing bile salts studied in simulated and ex vivo gastrointestinal media","volume":"441","author":"Hu","year":"2013","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2016.01.056_bb0320","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.ijpharm.2009.12.040","article-title":"Understanding the quality of protein loaded PLGA nanoparticles variability by plackett\u2013Burman design","volume":"389","author":"Rahman","year":"2010","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2016.01.056_bb0325","doi-asserted-by":"crossref","first-page":"e40","DOI":"10.1016\/j.jconrel.2010.07.048","article-title":"The effect of HP\u03b2CD on cyclosporine A in-vitro release from PLGA nanoparticles","volume":"148","author":"Hermans","year":"2010","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2016.01.056_bb0330","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.ijpharm.2011.05.012","article-title":"Preparation of polymeric nanoparticles of cyclosporin A using infrared pulsed laser","volume":"414","author":"Takebe","year":"2011","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2016.01.056_bb0335","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1021\/bm1008603","article-title":"Polysialic acid-based micelles for encapsulation of hydrophobic drugs","volume":"12","author":"Bader","year":"2011","journal-title":"Biomacromolecules"},{"key":"10.1016\/j.jconrel.2016.01.056_bb0340","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.ijpharm.2011.05.035","article-title":"Controlled poly (l-lactide-co-trimethylene carbonate) delivery system of cyclosporine A and rapamycine\u2013the effect of copolymer chain microstructure on drug release rate","volume":"414","author":"Jelonek","year":"2011","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2016.01.056_bb0345","doi-asserted-by":"crossref","first-page":"896141","DOI":"10.1155\/2012\/896141","article-title":"Immunosuppressive activity of size-controlled PEG-PLGA nanoparticles containing encapsulated cyclosporine A","volume":"2012","author":"Tang","year":"2012","journal-title":"J. Transplant."},{"key":"10.1016\/j.jconrel.2016.01.056_bb0350","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ejpb.2012.05.003","article-title":"Full factorial design, physicochemical characterisation and biological assessment of cyclosporine A loaded cationic nanoparticles","volume":"82","author":"Hermans","year":"2012","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.jconrel.2016.01.056_bb0355","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.ejps.2013.09.013","article-title":"Synthesis and evaluation of cyclosporine A-loaded polysialic acid\u2013polycaprolactone micelles for rheumatoid arthritis","volume":"51","author":"Wilson","year":"2014","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2016.01.056_bb0360","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1208\/s12248-009-9171-7","article-title":"Formulation and evaluation of a protein-loaded solid dispersions by non-destructive methods","volume":"12","author":"Rahman","year":"2010","journal-title":"AAPS J."},{"key":"10.1016\/j.jconrel.2016.01.056_bb0365","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.ijpharm.2014.03.051","article-title":"Silicon microfluidic flow focusing devices for the production of size-controlled PLGA based drug loaded microparticles","volume":"467","author":"Keohane","year":"2014","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2016.01.056_bb0370","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.ejpb.2010.09.012","article-title":"Novel cyclosporin A formulations using MPEG\u2013hexyl-substituted polylactide micelles: A suitability study","volume":"77","author":"Mondon","year":"2011","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.jconrel.2016.01.056_bb0375","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1177\/1091581814560032","article-title":"Synergistic effects of zinc oxide nanoparticles and fatty acids on toxicity to caco-2 cells","volume":"34","author":"Cao","year":"2015","journal-title":"Int. J. Toxicol."},{"issue":"Suppl. 4","key":"10.1016\/j.jconrel.2016.01.056_bb0380","first-page":"S475","article-title":"Nanoparticles made of multi-block copolymer of lactic acid and ethylene glycol containing periodic side-chain carboxyl groups for oral delivery of cyclosporine A","volume":"7","author":"Ankola","year":"2010","journal-title":"J. R. Soc. Interface"},{"key":"10.1016\/j.jconrel.2016.01.056_bb0385","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1166\/jbn.2011.1278","article-title":"Nanoparticulate delivery can improve peroral bioavailability of cyclosporine and match neoral cmax sparing the kidney from damage","volume":"7","author":"Ankola","year":"2011","journal-title":"J. Biomed. Nanotechnol."},{"key":"10.1016\/j.jconrel.2016.01.056_bb0390","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.tox.2015.01.017","article-title":"Drug-not carrier-dependent haematological and biochemical changes in a repeated dose study of cyclosporine encapsulated polyester nano-and micro-particles: size does not matter","volume":"330","author":"Venkatpurwar","year":"2015","journal-title":"Toxicology"},{"key":"10.1016\/j.jconrel.2016.01.056_bb0395","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1021\/mp200469a","article-title":"Enhanced oral absorption of hydrophobic and hydrophilic drugs using quaternary ammonium palmitoyl glycol chitosan nanoparticles","volume":"9","author":"Siew","year":"2011","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jconrel.2016.01.056_bb0400","first-page":"13","article-title":"Pharmacokinetics and enhanced oral bioavailability in beagle dogs of cyclosporine A encapsulated in glyceryl monooleate\/poloxamer 407 cubic nanoparticles","volume":"5","author":"Lai","year":"2010","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.jconrel.2016.01.056_bb0405","doi-asserted-by":"crossref","first-page":"458","DOI":"10.3109\/1061186X.2010.511224","article-title":"The effective therapy of cyclosporine A with drug delivery system in experimental colitis","volume":"19","author":"Fukata","year":"2011","journal-title":"J. Drug Target."},{"key":"10.1016\/j.jconrel.2016.01.056_bb0410","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1016\/j.ejpb.2013.08.003","article-title":"Supersaturated polymeric micelles for oral cyclosporine A delivery","volume":"85","author":"Yu","year":"2013","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.jconrel.2016.01.056_bb0415","doi-asserted-by":"crossref","first-page":"3927","DOI":"10.1096\/fj.10-154690","article-title":"Polylactide-cyclosporin A nanoparticles for targeted immunosuppression","volume":"24","author":"Azzi","year":"2010","journal-title":"FASEB J."},{"key":"10.1016\/j.jconrel.2016.01.056_bb0420","first-page":"903","article-title":"Liver-targeted cyclosporine A-encapsulated poly (lactic-co-glycolic) acid nanoparticles inhibit hepatitis C virus replication","volume":"10","author":"Jyothi","year":"2015","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.jconrel.2016.01.056_bb0425","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.jconrel.2011.01.010","article-title":"Development and characterization of cyclosporine A loaded nanoparticles for ocular drug delivery: cellular toxicity, uptake, and kinetic studies","volume":"151","author":"Aksungur","year":"2011","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2016.01.056_bb0430","doi-asserted-by":"crossref","first-page":"49","DOI":"10.3109\/02652048.2013.805839","article-title":"Chitosan nanoparticles for ocular delivery of cyclosporine A","volume":"31","author":"Basaran","year":"2013","journal-title":"J. Microencapsul."},{"key":"10.1016\/j.jconrel.2016.01.056_bb0435","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.ejpb.2012.02.014","article-title":"Novel micelle carriers for cyclosporin A topical ocular delivery: in vivo cornea penetration, ocular distribution and efficacy studies","volume":"81","author":"Di Tommaso","year":"2012","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.jconrel.2016.01.056_bb0440","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.ejpb.2012.07.014","article-title":"pH-sensitive polymeric nanoparticles to improve oral bioavailability of peptide\/protein drugs and poorly water-soluble drugs","volume":"82","author":"Wang","year":"2012","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.jconrel.2016.01.056_bb0445","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.ijpharm.2006.02.045","article-title":"Oral bioavailability of cyclosporine: solid lipid nanoparticles (SLN\u00ae) versus drug nanocrystals","volume":"317","author":"M\u00fcller","year":"2006","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2016.01.056_bb0450","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.ejpb.2013.01.029","article-title":"Biodistribution of nanostructured lipid carriers (NLCs) after intravenous administration to rats: influence of technological factors","volume":"84","author":"Beloqui","year":"2013","journal-title":"Eur. J. Pharm. Biopharm."},{"issue":"Part B","key":"10.1016\/j.jconrel.2016.01.056_bb0455","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.ejpb.2015.02.019","article-title":"Nanotherapies for the treatment of ocular diseases","volume":"95","author":"Reimondez-Troiti\u00f1o","year":"2015","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.jconrel.2016.01.056_bb0460","first-page":"3587","article-title":"Enhanced and sustained topical ocular delivery of cyclosporine A in thermosensitive hyaluronic acid-based in situ forming microgels","volume":"8","author":"Wu","year":"2013","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.jconrel.2016.01.056_bb0465","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.ijpharm.2012.12.033","article-title":"A new drug delivery system inhibits uveitis in an animal model after cataract surgery","volume":"443","author":"Eperon","year":"2013","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2016.01.056_bb0470","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.jconrel.2010.11.009","article-title":"Ophthalmic delivery of cyclosporine A by punctal plugs","volume":"150","author":"Gupta","year":"2011","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2016.01.056_bb0475","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.jconrel.2013.04.019","article-title":"In vivo distribution and ex vivo permeation of cyclosporine A prodrug aqueous formulations for ocular application","volume":"170","author":"Rodriguez-Aller","year":"2013","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2016.01.056_bb0480","first-page":"510","article-title":"Topical administration of cyclosporin A in a solid lipid nanoparticle formulation","volume":"64","author":"Kim","year":"2009","journal-title":"Pharmazie"},{"key":"10.1016\/j.jconrel.2016.01.056_bb0485","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1111\/exd.12051","article-title":"Penetration and biological effects of topically applied cyclosporin A nanoparticles in a human skin organ culture inflammatory model","volume":"21","author":"Fru\u0161i\u0107-Zlotkin","year":"2012","journal-title":"Exp. Dermatol."},{"key":"10.1016\/j.jconrel.2016.01.056_bb0490","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1080\/03639040802282904","article-title":"Recent developments in drug delivery to prolong allograft survival in lung transplant patients","volume":"35","author":"Watts","year":"2009","journal-title":"Drug Dev. Ind. Pharm."},{"key":"10.1016\/j.jconrel.2016.01.056_bb0495","first-page":"1269","article-title":"Physicochemical characterization and aerosol dispersion performance of organic solution advanced spray-dried cyclosporine A multifunctional particles for dry powder inhalation aerosol delivery","volume":"8","author":"Wu","year":"2013","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.jconrel.2016.01.056_bb0500","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1136\/bjo.2008.150011","article-title":"A comparative clinical trial of the efficacy of two different aqueous solutions of cyclosporine for the treatment of moderate-to-severe dry eye syndrome","volume":"94","author":"Baiza-Duran","year":"2010","journal-title":"Br. J. Ophthalmol."},{"key":"10.1016\/j.jconrel.2016.01.056_bb0505","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/j.ophtha.2012.09.035","article-title":"A novel cyclosporine a drug-delivery system for prevention of human corneal rejection after high-risk keratoplasty: a clinical study","volume":"120","author":"Shi","year":"2013","journal-title":"Ophthalmology"}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365916300517?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365916300517?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,4,26]],"date-time":"2019-04-26T20:08:15Z","timestamp":1556309295000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365916300517"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3]]},"references-count":101,"alternative-id":["S0168365916300517"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2016.01.056","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2016,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Reformulating cyclosporine A (CsA): More than just a life cycle management strategy","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2016.01.056","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}